Neurocrine Biosciences and Voyager Therapeutics Announce Publication of Phase 1b Trial Results of VY-AADC for Parkinson’s Disease in the Annals of Neurology
March 28, 2019 16:15 ET
|
Voyager Therapeutics, Inc.
SAN DIEGO and CAMBRIDGE, Mass., March 28, 2019 (GLOBE NEWSWIRE) -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) and Voyager Therapeutics, Inc. (NASDAQ: VYGR) today announced the publication of...
Herantis Pharman vuosikertomus 2018 julkaistu
March 20, 2019 03:00 ET
|
Herantis Pharma Oyj
Herantis Pharman vuosikertomus 2018 julkaistu Herantis Pharma Oyj Yhtiötiedote 20.3.2019 kello 9:00 Herantis Pharma Oyj:n vuosikertomus vuodelta 2018 on julkaistu tänään. Vuosikertomus sisältää...
Herantis Pharma’s Annual Report 2018 published
March 20, 2019 03:00 ET
|
Herantis Pharma Oyj
Herantis Pharma’s Annual Report 2018 published Herantis Pharma Plc Company release 20 March 2019 at 9:00 am Herantis Pharma Plc’s Annual Report for the year 2018 has been published today. The Annual...
Voyager Therapeutics and AbbVie Announce Collaboration to Develop Vectorized Antibodies to Treat Parkinson’s Disease and Other Synucleinopathies
February 22, 2019 08:00 ET
|
Voyager Therapeutics, Inc.
Deal expands collaborative efforts on vectorized antibodies to target pathological species of alpha-synuclein Voyager to receive $65 million upfront and up to $245 million in preclinical and Phase 1...
Neurocrine Biosciences and Voyager Therapeutics Form Strategic Development and Commercialization Collaboration for Parkinson’s Disease and Friedreich’s Ataxia
January 29, 2019 07:00 ET
|
Voyager Therapeutics, Inc.; Neurocrine Biosciences, Inc.
Collaboration leverages strengths and efforts of both companies towards developing and commercializing life-changing treatments for severe neurological diseases Neurocrine Biosciences gains...
Voyager Therapeutics Provides Updates for VY-AADC Clinical Program for Parkinson’s Disease
January 07, 2019 07:07 ET
|
Voyager Therapeutics, Inc.
Voyager to increase the size of RESTORE-1 Phase 2 trial and to conduct a similarly-sized RESTORE-2 Phase 3 trial VY-AADC clinical program updates incorporate FDA feedback from Type B meeting ...
Adamas Announces Issuance of New U.S. Patent Covering GOCOVRI™
December 18, 2018 16:30 ET
|
Adamas Pharmaceuticals, Inc.
EMERYVILLE, Calif., Dec. 18, 2018 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a fully-integrated pharmaceutical company pioneering time-dependent medicines for central nervous...
Denali Therapeutics Announces First Patient Dosed in Phase 1b Study of DNL201 for Parkinson’s Disease
December 10, 2018 09:00 ET
|
Denali Therapeutics Inc.
Phase 1b study includes Parkinson’s disease patients with and without a genetic LRRK2 mutation SOUTH SAN FRANCISCO, Calif., Dec. 10, 2018 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ:...
Voyager Therapeutics Announces First Patient Dosed in RESTORE-1, a Phase 2 Trial of VY-AADC Gene Therapy for the Treatment of Parkinson’s Disease
December 10, 2018 07:10 ET
|
Voyager Therapeutics, Inc.
CAMBRIDGE, Mass., Dec. 10, 2018 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ: VYGR), a clinical-stage gene therapy company focused on developing life-changing treatments for severe...
International Stem Cell Corporation Announces Strong Financial Results for the Three and Nine-Months ended September 30, 2018
November 15, 2018 08:30 ET
|
International Stem Cell Corporation
Increases in Revenues and Profit MarginsNet Income Realized for the Quarter CARLSBAD, Calif., Nov. 15, 2018 (GLOBE NEWSWIRE) -- International Stem Cell Corporation (OTCQB:ISCO)...